Infused therapy and survival in older patients diagnosed with metastatic breast cancer who received trastuzumab

Robert I. Griffiths, Deepa Lalla, Robert J. Herbert, Justin F. Doan, Melissa G. Brammer, Mark D. Danese

Research output: Contribution to journalArticle

Abstract

We used Surveillance, Epidemiology, and End ResultsMedicare data (2000-2006) to describe treatment and survival in women diagnosed with metastatic breast cancer (MBC) who received trastuzumab. There were 610 patients with a mean age of 74 years. Overall, 32% received trastuzumab alone and 47% received trastuzumab plus a taxane. In multivariate analysis, trastuzumab plus chemotherapy was associated with a lower adjusted cancer mortality rate (Hazard Ratio [HRé 0.54; 95% Confidence Interval [CIé 0.39-0.74; p <.001) than trastuzumab alone among patients who received trastuzumab as part of first-line therapy. Adding chemotherapy to first-line trastuzumab for metastatic breast cancer is associated with improved cancer survival.

Original languageEnglish (US)
Pages (from-to)573-584
Number of pages12
JournalCancer Investigation
Volume29
Issue number9
DOIs
StatePublished - Nov 2011

Fingerprint

Breast Neoplasms
Survival
Therapeutics
Drug Therapy
Trastuzumab
Neoplasms
Epidemiology
Multivariate Analysis
Confidence Intervals
Mortality

Keywords

  • Breast cancers
  • Chemotherapy
  • Outcomes research

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Griffiths, R. I., Lalla, D., Herbert, R. J., Doan, J. F., Brammer, M. G., & Danese, M. D. (2011). Infused therapy and survival in older patients diagnosed with metastatic breast cancer who received trastuzumab. Cancer Investigation, 29(9), 573-584. https://doi.org/10.3109/07357907.2011.616251

Infused therapy and survival in older patients diagnosed with metastatic breast cancer who received trastuzumab. / Griffiths, Robert I.; Lalla, Deepa; Herbert, Robert J.; Doan, Justin F.; Brammer, Melissa G.; Danese, Mark D.

In: Cancer Investigation, Vol. 29, No. 9, 11.2011, p. 573-584.

Research output: Contribution to journalArticle

Griffiths, Robert I. ; Lalla, Deepa ; Herbert, Robert J. ; Doan, Justin F. ; Brammer, Melissa G. ; Danese, Mark D. / Infused therapy and survival in older patients diagnosed with metastatic breast cancer who received trastuzumab. In: Cancer Investigation. 2011 ; Vol. 29, No. 9. pp. 573-584.
@article{64b2adfe3c9640f7af4729c5f0bfec77,
title = "Infused therapy and survival in older patients diagnosed with metastatic breast cancer who received trastuzumab",
abstract = "We used Surveillance, Epidemiology, and End ResultsMedicare data (2000-2006) to describe treatment and survival in women diagnosed with metastatic breast cancer (MBC) who received trastuzumab. There were 610 patients with a mean age of 74 years. Overall, 32{\%} received trastuzumab alone and 47{\%} received trastuzumab plus a taxane. In multivariate analysis, trastuzumab plus chemotherapy was associated with a lower adjusted cancer mortality rate (Hazard Ratio [HR{\'e} 0.54; 95{\%} Confidence Interval [CI{\'e} 0.39-0.74; p <.001) than trastuzumab alone among patients who received trastuzumab as part of first-line therapy. Adding chemotherapy to first-line trastuzumab for metastatic breast cancer is associated with improved cancer survival.",
keywords = "Breast cancers, Chemotherapy, Outcomes research",
author = "Griffiths, {Robert I.} and Deepa Lalla and Herbert, {Robert J.} and Doan, {Justin F.} and Brammer, {Melissa G.} and Danese, {Mark D.}",
year = "2011",
month = "11",
doi = "10.3109/07357907.2011.616251",
language = "English (US)",
volume = "29",
pages = "573--584",
journal = "Cancer Investigation",
issn = "0735-7907",
publisher = "Informa Healthcare",
number = "9",

}

TY - JOUR

T1 - Infused therapy and survival in older patients diagnosed with metastatic breast cancer who received trastuzumab

AU - Griffiths, Robert I.

AU - Lalla, Deepa

AU - Herbert, Robert J.

AU - Doan, Justin F.

AU - Brammer, Melissa G.

AU - Danese, Mark D.

PY - 2011/11

Y1 - 2011/11

N2 - We used Surveillance, Epidemiology, and End ResultsMedicare data (2000-2006) to describe treatment and survival in women diagnosed with metastatic breast cancer (MBC) who received trastuzumab. There were 610 patients with a mean age of 74 years. Overall, 32% received trastuzumab alone and 47% received trastuzumab plus a taxane. In multivariate analysis, trastuzumab plus chemotherapy was associated with a lower adjusted cancer mortality rate (Hazard Ratio [HRé 0.54; 95% Confidence Interval [CIé 0.39-0.74; p <.001) than trastuzumab alone among patients who received trastuzumab as part of first-line therapy. Adding chemotherapy to first-line trastuzumab for metastatic breast cancer is associated with improved cancer survival.

AB - We used Surveillance, Epidemiology, and End ResultsMedicare data (2000-2006) to describe treatment and survival in women diagnosed with metastatic breast cancer (MBC) who received trastuzumab. There were 610 patients with a mean age of 74 years. Overall, 32% received trastuzumab alone and 47% received trastuzumab plus a taxane. In multivariate analysis, trastuzumab plus chemotherapy was associated with a lower adjusted cancer mortality rate (Hazard Ratio [HRé 0.54; 95% Confidence Interval [CIé 0.39-0.74; p <.001) than trastuzumab alone among patients who received trastuzumab as part of first-line therapy. Adding chemotherapy to first-line trastuzumab for metastatic breast cancer is associated with improved cancer survival.

KW - Breast cancers

KW - Chemotherapy

KW - Outcomes research

UR - http://www.scopus.com/inward/record.url?scp=80054859025&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80054859025&partnerID=8YFLogxK

U2 - 10.3109/07357907.2011.616251

DO - 10.3109/07357907.2011.616251

M3 - Article

C2 - 21929325

AN - SCOPUS:80054859025

VL - 29

SP - 573

EP - 584

JO - Cancer Investigation

JF - Cancer Investigation

SN - 0735-7907

IS - 9

ER -